Urolithin A plus EGCG enhances mitophagy associated pathways, mitochondrial dynamics, and bioenergetic function in humanized amyloid-β knock-in mice.
Key claim: Co-administration of urolithin A and EGCG enhances mitophagy, promotes mitochondrial fusion and biogenesis, reduces amyloid-beta pathology, and improves cognitive performance in humanized amyloid-beta knock-in mice.
Abstract
Mitochondrial dysfunction and impaired mitochondrial quality control are increasingly recognized as important contributors to Alzheimer’s disease (AD). Urolithin A is a mitophagy-promoting metabolite, whereas epigallocatechin-3-gallate (EGCG) has antioxidant, anti-inflammatory, and anti-amyloidogenic properties. In the present study, we evaluated the effects of urolithin A alone and in combination with EGCG on mitochondrial homeostasis in humanized amyloid-β knock-in (hAbKI) mice. Three-month-old hAbKI mice were treated with urolithin A (2.5 mg/kg) or urolithin A plus EGCG (25 mg/kg) by intraperitoneal injection three times per week for four months. At seven months of age, mitochondrial dynamics, mitochondrial biogenesis, mitophagy/autophagy-associated pathways, mitochondrial ultrastructure, ATP production, oxidative stress, synaptic and dendritic markers, glial and neuronal proteins, soluble Aβ40 and Aβ42 levels, and behavioral performance were evaluated. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis showed reduced expression of the mitochondrial fission genes Drp1 and Fis1 and increased expression of the fusion genes Mfn1, Mfn2, and Opa1 following treatment. Mitochondrial biogenesis-associated genes, including PGC1α, Nrf1 and TFAM, were also increased. These transcriptional changes were supported by immunoblotting analyses. Treatment further increased mitophagy- and autophagy-associated markers, including PINK1, Parkin, ATG5, LC3B, Beclin1, and BCL2. Transmission electron microscopy demonstrated increased mitochondrial length, reduced mitochondrial fragmentation. These changes were accompanied by increased mitochondrial ATP levels and reduced hydrogen peroxide and 4-hydroxynonenal levels. Both treatment regimens were also associated with increased synaptic and dendritic measures, reduced Iba1 and GFAP expression, increased NeuN levels, lower soluble Aβ40 and Aβ42 concentrations, and improved performance in several behavioral tasks. Across multiple mitochondrial and neuronal endpoints, the magnitude of the response was greater following combined urolithin A and EGCG treatment. These findings indicate that urolithin A modulates multiple components of mitochondrial quality control in hAbKI mice and that co-treatment with EGCG is associated with broader improvements in mitochondrial and neuronal homeostasis. Further studies are required to define the specific contribution of EGCG and to directly assess mitophagic flux and mitochondrial respiration.
Why this matters
[animal-model] This study places mitochondrial clearance, fusion, biogenesis, and bioenergetic function within a shared treatment-response pattern accompanying reduced amyloid pathology and improved cognition in an Alzheimer’s mouse model. [animal-model] The findings do not establish which mitochondrial processes cause the cognitive effects, and the humanized amyloid model remains preclinical rather than evidence that a urolithin A–EGCG supplement combination prevents or treats human cognitive decline.